Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL710885 | 0.83 | PPARD (0.54) | PPARDTSHRSMN1; SMN2POLBCYP1A2 | |
| SCHEMBL7709958 | 0.82 | TSHR (0.40) | PPARDTSHRTP53TDP1ALDH1A1 | |
| SCHEMBL1276805 | 0.81 | PPARD (0.44) | PPARDTSHRSMN1; SMN2POLBCYP1A2 | |
| SCHEMBL15951709 | 0.79 | PPARD (0.48) | PPARDTSHRTDP1SMN1; SMN2POLB | |
| SCHEMBL7425644 | 0.77 | PPARD (0.56) | PPARDTSHRTP53TDP1ALDH1A1 | |
| SCHEMBL10877243 | 0.77 | PPARD (0.57) | PPARDTSHRSMN1; SMN2POLB | |
| SCHEMBL19513947 | 0.77 | PPARD (0.47) | PPARDTSHRTDP1SMN1; SMN2POLB | |
| SCHEMBL1276806 | 0.77 | PPARD (0.43) | PPARDTSHRSMN1; SMN2POLBCYP1A2 | |
| SCHEMBL11663536 | 0.77 | TSHR (0.58) | PPARDTSHRTP53TDP1ALDH1A1 | |
| SCHEMBL15951765 | 0.76 | DGKA (0.47) | PPARDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901072-B2 | Glycopeptide and lipoglycopeptide antibiotics with improved solubility | THE MEDICINES COMPANY (US) | 2014-12-02 | — | — | US | disclosed |
| US-20120149632-A1 | GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS WITH IMPROVED SOLUBILITY | THE MEDICINES COMPANY (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2011019839-A2 | GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS WITH IMPROVED SOLUBILITY | THE MEDICINES COMPANY (US) | 2011-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149632-A1 | GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS WITH IMPROVED SOLUBILITY | NGLY1, LGALS3BP, GYPA | PPARD 3782/4885TSHR 3204/4885TP53 972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.